{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,27]],"date-time":"2026-09-27T18:24:02Z","timestamp":1790533442569,"version":"4.1.0"},"reference-count":44,"publisher":"MDPI AG","issue":"23","license":[{"start":{"date-parts":[[2022,11,27]],"date-time":"2022-11-27T00:00:00Z","timestamp":1669507200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100003196","name":"AP, Ministero della Salute, Ricerca Corrente IRCCS, Istituto Pascale","doi-asserted-by":"publisher","award":["L2\/11"],"award-info":[{"award-number":["L2\/11"]}],"id":[{"id":"10.13039\/501100003196","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Cancers"],"abstract":"<jats:p>(1) Background: Consolidation therapy is an emerging strategy for patients with relapsed\/refractory (RR) Hodgkin Lymphoma (HL) at high risk of failing salvage autologous stem cell transplantation (ASCT). (2) Objectives: To assess the safety and effectiveness of PD1-blockade consolidation for these high-risk patients. (3) Design: Multi-center retrospective analysis. (4) Methods: We identified 26 patients given anti-PD1 consolidation, from June 2016 to May 2020. (5) Results: Patients displayed the following risk factors: refractory disease (69%), relapse &lt; 12 months from upfront therapy (15%), \u22652 lines of salvage therapy (73%), extranodal disease (65%). Nineteen patients (73%) had \u22653 of these factors. In addition, 16 patients (61%) also displayed PET-positive (Deauville \u2265 4) disease before ASCT. Treatment-related adverse events (TRAEs), never graded &gt; 3, occurred in 12 patients (46.15%) and mainly included skin rashes (41.7%), transaminitis (33.3%), and thyroid hypofunction (25%). Patients completed a median of 13 courses (range 6\u201330). At a median follow-up of 25.8 months post-ASCT, the median progression-free (PFS) was 42.6 months, with a 2-year PFS and overall survival rates of 79% and 87%, respectively. (6) Conclusions: Post-ASCT consolidation with anti-PD1 is feasible and effective. Further studies are warranted to define the optimal treatment length and patients\u2019 subsets more likely to benefit from this approach.<\/jats:p>","DOI":"10.3390\/cancers14235846","type":"journal-article","created":{"date-parts":[[2022,11,28]],"date-time":"2022-11-28T07:01:30Z","timestamp":1669618890000},"page":"5846","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":6,"title":["Anti-PD1 Consolidation in Patients with Hodgkin Lymphoma at High Risk of Relapse after Autologous Stem Cell Transplantation: A Multicenter Real-Life Study"],"prefix":"10.3390","volume":"14","author":[{"given":"Rosaria","family":"De Filippi","sequence":"first","affiliation":[{"name":"Department of Clinical Medicine and Surgery, Universit\u00e0 degli Studi Federico II, 80131 Naples, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gianpaolo","family":"Marcacci","sequence":"additional","affiliation":[{"name":"Hematology-Oncology and Stem Cell Transplantation Unit, Istituto Nazionale Tumori, Fondazione \u2018G. Pascale\u2019, IRCCS, 80131 Naples, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Enrico","family":"Derenzini","sequence":"additional","affiliation":[{"name":"Oncohematology Division, IEO European Institute of Oncology IRCCS, Department of Health Sciences, University of Milan, 20129 Milan, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maurizio","family":"Musso","sequence":"additional","affiliation":[{"name":"Department of Oncology, Hematology and BMT Unit, Casa di Cura La Maddalena, 90145 Palermo, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daniela","family":"Donnarumma","sequence":"additional","affiliation":[{"name":"Hematology-Oncology and Stem Cell Transplantation Unit, Istituto Nazionale Tumori, Fondazione \u2018G. Pascale\u2019, IRCCS, 80131 Naples, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Emanuela","family":"Morelli","sequence":"additional","affiliation":[{"name":"Hematology-Oncology and Stem Cell Transplantation Unit, Istituto Nazionale Tumori, Fondazione \u2018G. Pascale\u2019, IRCCS, 80131 Naples, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Caterina","family":"Patti","sequence":"additional","affiliation":[{"name":"Division of Onco-Hematology, Azienda Villa Sofia-Cervello, 90146 Palermo, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alessio Maria Edoardo","family":"Maraglino","sequence":"additional","affiliation":[{"name":"Oncohematology Division, IEO European Institute of Oncology IRCCS, Department of Health Sciences, University of Milan, 20129 Milan, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Renato","family":"Scalone","sequence":"additional","affiliation":[{"name":"Department of Oncology, Hematology and BMT Unit, Casa di Cura La Maddalena, 90145 Palermo, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Luigia","family":"Simeone","sequence":"additional","affiliation":[{"name":"Hematology-Oncology and Stem Cell Transplantation Unit, Istituto Nazionale Tumori, Fondazione \u2018G. Pascale\u2019, IRCCS, 80131 Naples, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1299-6573","authenticated-orcid":false,"given":"Cristina","family":"Becchimanzi","sequence":"additional","affiliation":[{"name":"Hematology-Oncology and Stem Cell Transplantation Unit, Istituto Nazionale Tumori, Fondazione \u2018G. Pascale\u2019, IRCCS, 80131 Naples, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sara","family":"Mele","sequence":"additional","affiliation":[{"name":"Hematology-Oncology and Stem Cell Transplantation Unit, Istituto Nazionale Tumori, Fondazione \u2018G. Pascale\u2019, IRCCS, 80131 Naples, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0567-2709","authenticated-orcid":false,"given":"Stefania","family":"Crisci","sequence":"additional","affiliation":[{"name":"Hematology-Oncology and Stem Cell Transplantation Unit, Istituto Nazionale Tumori, Fondazione \u2018G. Pascale\u2019, IRCCS, 80131 Naples, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2585-7073","authenticated-orcid":false,"given":"Fortunato","family":"Morabito","sequence":"additional","affiliation":[{"name":"Hematology-Oncology and Stem Cell Transplantation Unit, Istituto Nazionale Tumori, Fondazione \u2018G. Pascale\u2019, IRCCS, 80131 Naples, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9425-9026","authenticated-orcid":false,"given":"Antonio","family":"Pinto","sequence":"additional","affiliation":[{"name":"Hematology-Oncology and Stem Cell Transplantation Unit, Istituto Nazionale Tumori, Fondazione \u2018G. Pascale\u2019, IRCCS, 80131 Naples, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2022,11,27]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"322","DOI":"10.6004\/jnccn.2022.0021","article-title":"NCCN Guidelines\u00ae Insights: Hodgkin Lymphoma, Version 2.2022","volume":"20","author":"Hoppe","year":"2022","journal-title":"J. Natl. Compr. Canc. Netw."},{"key":"ref_2","first-page":"1","article-title":"High-dose chemotherapy followed by autologous stem cell transplantation for patients with relapsed\/refractory Hodgkin lymphoma","volume":"6","author":"Rancea","year":"2013","journal-title":"Cochrane Database Syst. Rev."},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"801","DOI":"10.1182\/blood.V89.3.801","article-title":"High-dose therapy and autologous hematopoietic progenitor cell transplantation for recurrent or refractory Hodgkin\u2019s disease: Analysis of the Stanford University results and prognostic indices","volume":"89","author":"Horning","year":"1997","journal-title":"Blood"},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1038\/sj.bmt.1700838","article-title":"Prognostic factors for survival after high-dose therapy and autologous stem cell transplantation for patients with relapsing Hodgkin\u2019s disease: Analysis of 280 patients from the French registry. Soci\u00e9t\u00e9 Fran\u00e7aise de Greffe de Mo\u00eblle","volume":"20","author":"Brice","year":"1997","journal-title":"Bone Marrow Transplant."},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"625","DOI":"10.1093\/annonc\/mdi119","article-title":"Grupo Espa\u00f1ol de Linfomas\/Trasplante Aut\u00f3logo de M\u00e9dula Osea Cooperative Group. Prognostic factors affecting long-term outcome after stem cell transplantation in Hodgkin\u2019s lymphoma autografted after a first relapse","volume":"16","author":"Sureda","year":"2005","journal-title":"Ann. Oncol."},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"1665","DOI":"10.1182\/blood-2011-10-388058","article-title":"Normalization of pre-ASCT, FDG-PET imaging with second-line, non-cross-resistant, chemotherapy programs improves event-free survival in patients with Hodgkin lymphoma","volume":"119","author":"Moskowitz","year":"2012","journal-title":"Blood"},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"1969","DOI":"10.3109\/10428194.2014.981174","article-title":"Recurrent Hodgkin lymphoma: Toward a new definition of candidates for autologous stem cell transplant in the era of positron emission tomography scan and novel agents","volume":"56","author":"Pinto","year":"2015","journal-title":"Leuk. Lymphoma"},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"1689","DOI":"10.1182\/blood-2017-09-772673","article-title":"Transplant strategies in relapsed\/refractory Hodgkins lymphoma","volume":"131","author":"Shah","year":"2018","journal-title":"Blood"},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"1853","DOI":"10.1016\/S0140-6736(15)60165-9","article-title":"Brentuximab vedotin as consolidation therapy after autologous stem-cell transplantation in patients with Hodgkin\u2019s lymphoma at risk of relapse or progression (AETHERA): A randomised, double-blind, placebo-controlled, phase 3 trial","volume":"385","author":"Moskowitz","year":"2015","journal-title":"Lancet"},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"1352","DOI":"10.1093\/annonc\/mdx072","article-title":"Risk factors and a prognostic score for survival after autologous stem-cell transplantation for relapsed or refractory Hodgkin lymphoma","volume":"28","author":"Casasnovas","year":"2017","journal-title":"Ann. Oncol."},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"879","DOI":"10.1002\/ajh.24792","article-title":"Outcomes of patients with relapsed\/refractory Hodgkin lymphoma progressing after autologous stem cell transplant in the current era of novel therapeutics: A retrospective analysis","volume":"92","author":"Bair","year":"2017","journal-title":"Am. J. Hematol."},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"813","DOI":"10.1080\/10428194.2021.2002322","article-title":"Improved post-ASCT survival of relapsed\/refractory classical Hodgkin lymphoma patients in the era of novel agents","volume":"63","author":"Shah","year":"2022","journal-title":"Leuk. Lymphoma"},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"1646","DOI":"10.1038\/s41375-022-01563-8","article-title":"The outcome of patients with Hodgkin lymphoma and early relapse after autologous stem cell transplant has improved in recent years","volume":"36","author":"Bazarbachi","year":"2022","journal-title":"Leukemia"},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"899","DOI":"10.3324\/haematol.2021.278311","article-title":"Improved outcomes of high-risk relapsed Hodgkin lymphoma patients after high-dose chemotherapy: A 15-year analysis","volume":"107","author":"Nieto","year":"2022","journal-title":"Haematologica"},{"key":"ref_15","doi-asserted-by":"crossref","unstructured":"Satou, A., Takahara, T., and Nakamura, S. (2022). An Update on the Pathology and Molecular Features of Hodgkin Lymphoma. Cancers, 14.","DOI":"10.3390\/cancers14112647"},{"key":"ref_16","doi-asserted-by":"crossref","unstructured":"Taylor, J.G., Truelove, E., Clear, A., Calaminici, M., and Gribben, J.G. (2022). PDL1 shapes the classical Hodgkin lymphoma microenvironment without inducing T cell exhaustion. Haematologica.","DOI":"10.3324\/haematol.2022.280014"},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"512","DOI":"10.1016\/S1470-2045(21)00005-X","article-title":"Pembrolizumab versus brentuximab vedotin in relapsed or refractory classical Hodgkin lymphoma (KEYNOTE-204): An interim analysis of a multicentre, randomised, open-label, phase 3 study","volume":"22","author":"Kuruvilla","year":"2021","journal-title":"Lancet Oncol."},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"122","DOI":"10.1002\/hon.74_2879","article-title":"Nivolumab for relapsed or refractory (r\/r) classical hodgkin lymphoma (cHL) after autologous transplantation: 5-year overall survival from the phase 2 checkmate 205 study","volume":"39","author":"Ansell","year":"2021","journal-title":"Hematol. Oncol."},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"520","DOI":"10.1182\/blood.2020007900","article-title":"How I incorporate novel agents into the treatment of classical Hodgkin lymphoma","volume":"138","author":"Epperla","year":"2021","journal-title":"Blood"},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"284","DOI":"10.1016\/S1470-2045(15)70013-6","article-title":"PET-adapted sequential salvage therapy with brentuximab vedotin followed by augmented ifosamide, carboplatin, and etoposide for patients with relapsed and refractory Hodgkin\u2019s lymphoma: A non-randomised, open-label, single-centre, phase 2 study","volume":"16","author":"Moskowitz","year":"2015","journal-title":"Lancet Oncol."},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"3605","DOI":"10.1182\/blood.2022015423","article-title":"Response-adapted anti-PD-1-based salvage therapy for Hodgkin lymphoma with nivolumab alone or in combination with ICE","volume":"139","author":"Mei","year":"2022","journal-title":"Blood"},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"3109","DOI":"10.1200\/JCO.21.01056","article-title":"Phase II Trial of Pembrolizumab Plus Gemcitabine, Vinorelbine, and Liposomal Doxorubicin as Second-Line Therapy for Relapsed or Refractory Classical Hodgkin Lymphoma","volume":"39","author":"Moskowitz","year":"2021","journal-title":"J Clin Oncol."},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"427","DOI":"10.1182\/blood.2020009178","article-title":"Brentuximab vedotin in combination with nivolumab in relapsed or refractory Hodgkin lymphoma: 3-year study results","volume":"138","author":"Advani","year":"2021","journal-title":"Blood"},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"2639","DOI":"10.1182\/blood-2018-07-861641","article-title":"Five-year PFS from the AETHERA trial of brentuximab vedotin for Hodgkin lymphoma at high risk of progression or relapse","volume":"132","author":"Moskowitz","year":"2018","journal-title":"Blood"},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1182\/blood.2019000215","article-title":"PD-1 blockade with pembrolizumab for classical Hodgkin lymphoma after autologous stem cell transplantation","volume":"134","author":"Armand","year":"2019","journal-title":"Blood"},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"32.e1","DOI":"10.1016\/j.jtct.2021.10.010","article-title":"Immune Reconstitution following High-Dose Chemotherapy and Autologous Stem Cell Transplantation with or without Pembrolizumab Maintenance Therapy in Patients with Lymphoma","volume":"28","author":"Merryman","year":"2022","journal-title":"Transpl. Cell Ther."},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1182\/blood-2020-136384","article-title":"Consolidation with nivolumab and brentuximab vedotin after autologous hematopoietic cell transplantation in patients with high-risk Hodgkin lymphoma","volume":"136","author":"Herrera","year":"2020","journal-title":"Blood"},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"2455","DOI":"10.1182\/blood-2021-148139","article-title":"A Phase II Single Arm Study of Nivolumab As Maintenance Therapy after Autologous Stem Cell Transplantation in Patients with Hodgkin Lymphoma at Risk of Relapse or Progression","volume":"138","author":"Bachier","year":"2021","journal-title":"Blood"},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"3059","DOI":"10.1200\/JCO.2013.54.8800","article-title":"Recommendations for initial evaluation, staging, and response assessment of Hodgkin and non-Hodgkin lymphoma: The Lugano classification","volume":"32","author":"Cheson","year":"2014","journal-title":"J. Clin. Oncol."},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"489","DOI":"10.1186\/s12967-021-03134-4","article-title":"Body mass index is not associated with survival outcomes and immune-related adverse events in patients with Hodgkin lymphoma treated with the immune checkpoint inhibitor nivolumab","volume":"19","author":"Morabito","year":"2021","journal-title":"J. Transl. Med."},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"iv119","DOI":"10.1093\/annonc\/mdx225","article-title":"ESMO Guidelines Committee. Management of toxicities from immunotherapy: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up","volume":"28","author":"Haanen","year":"2017","journal-title":"Ann. Oncol."},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"82","DOI":"10.1111\/bjh.18183","article-title":"Chemotherapy after PD-1 inhibitors in relapsed\/refractory Hodgkin lymphoma: Outcomes and clonal evolution dynamics","volume":"198","author":"Calabretta","year":"2022","journal-title":"Br. J. Haematol."},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"7830","DOI":"10.1002\/cam4.3262","article-title":"Effectiveness of chemotherapy after anti-PD-1 blockade failure for relapsed and refractory Hodgkin lymphoma","volume":"9","author":"Casadei","year":"2020","journal-title":"Cancer Med."},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"878","DOI":"10.1634\/theoncologist.2020-0167","article-title":"Checkpoint blockade treatment may sensitize Hodgkin lymphoma to subsequent therapy","volume":"25","author":"Carreau","year":"2020","journal-title":"Oncologist"},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"1648","DOI":"10.1182\/bloodadvances.2020003556","article-title":"Autologous stem cell transplantation after anti-PD-1 therapy for multiply relapsed or refractory Hodgkin lymphoma","volume":"5","author":"Merryman","year":"2021","journal-title":"Blood Adv."},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"165","DOI":"10.1186\/s40425-019-0645-6","article-title":"Delayed immune-related events (DIRE) after discontinuation of immunotherapy: Diagnostic hazard of autoimmunity at a distance","volume":"7","author":"Couey","year":"2019","journal-title":"J. Immunother. Cancer"},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"3167","DOI":"10.1200\/JCO.2009.26.7609","article-title":"Phase I study of single-agent anti-programmed Death-1 (MDX-1106) in refractory solid tumors: Safety, clinical activity, pharmacodynamics, and immunologic correlates","volume":"28","author":"Brahmer","year":"2010","journal-title":"J. Clin. Oncol."},{"key":"ref_38","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1016\/j.ejca.2019.04.006","article-title":"Long-term efficacy of anti-PD1 therapy in Hodgkin lymphoma with and without allogenic stem cell transplantation","volume":"115","author":"Manson","year":"2019","journal-title":"Eur. J. Cancer"},{"key":"ref_39","doi-asserted-by":"crossref","first-page":"1144","DOI":"10.1007\/s00259-020-05015-2","article-title":"Risk of relapse after anti-PD1 discontinuation in patients with Hodgkin lymphoma","volume":"48","author":"Manson","year":"2021","journal-title":"Eur. J. Nucl. Med. Mol. Imaging"},{"key":"ref_40","doi-asserted-by":"crossref","first-page":"942","DOI":"10.1200\/JCO.2017.77.3994","article-title":"Major histocompatibility complex class II and programmed death ligand 1 expression predict outcome after programmed death 1 blockade in classic Hodgkin Lymphoma","volume":"36","author":"Roemer","year":"2018","journal-title":"J. Clin. Oncol."},{"key":"ref_41","doi-asserted-by":"crossref","first-page":"1147","DOI":"10.1158\/1078-0432.CCR-21-2023","article-title":"Tislelizumab for Relapsed\/Refractory Classical Hodgkin Lymphoma: 3-Year Follow-up and Correlative Biomarker Analysis","volume":"28","author":"Song","year":"2022","journal-title":"Clin. Cancer Res."},{"key":"ref_42","doi-asserted-by":"crossref","first-page":"126","DOI":"10.1038\/s41408-021-00518-z","article-title":"Latest advances in the management of classical Hodgkin lymphoma: The era of novel therapies","volume":"11","author":"Mohty","year":"2021","journal-title":"Blood Cancer J."},{"key":"ref_43","doi-asserted-by":"crossref","first-page":"310","DOI":"10.1056\/NEJMoa2206125","article-title":"Overall Survival with Brentuximab Vedotin in Stage III or IV Hodgkin\u2019s Lymphoma","volume":"387","author":"Ansell","year":"2022","journal-title":"N. Engl. J. Med."},{"key":"ref_44","doi-asserted-by":"crossref","unstructured":"Samara, Y., and Mei, M. (2022). Autologous Stem Cell Transplantation in Hodgkin Lymphoma-Latest Advances in the Era of Novel Therapies. Cancers, 14.","DOI":"10.3390\/cancers14071738"}],"container-title":["Cancers"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2072-6694\/14\/23\/5846\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,11]],"date-time":"2025-10-11T01:27:49Z","timestamp":1760146069000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2072-6694\/14\/23\/5846"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,11,27]]},"references-count":44,"journal-issue":{"issue":"23","published-online":{"date-parts":[[2022,12]]}},"alternative-id":["cancers14235846"],"URL":"https:\/\/doi.org\/10.3390\/cancers14235846","relation":{},"ISSN":["2072-6694"],"issn-type":[{"value":"2072-6694","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,11,27]]}}}